[Roles of potassium channel in effects of resveratrol on isolated myocardial contractility and heart rate research in guinea pig].
OBJECTIVE
To study the effects of resvaratrol derivatives on spontaneous HR and CF of isolated guinea pig atrium.


METHODS
The dose-effect curve of resvaratrol was observed. The possible mechanism of potassium channels responsible for changes of CF and HR after administering with resvaratrol was measured.


RESULTS
Resvaratrol reduced the spontaneous HR and weakened the CF in a dose-dependent manner ranging from 10(-6) to 3 x 10(-4) mol x L(-1) (P < 0.05). As compared with Res group, the effects were partly blocked by Gli (P < 0.05) and TEA (P < 0.01), but not blocked by 4-AP, BaCl2, Atropine.


CONCLUSIONS
Resvaratrol can induce negative chronotropic action and negative (inotropic action. The mechanism(s) may relate to the opening of K(ATP) and Kc(Ca).
Wang
Gui-ying
GY
Department of Physiology, Basic Medical College, Hebei Medical University, Shijiazhuang 050091, China. ccwgy@163.com
Song
Cui-miao
CM
Zhang
Li-nan
LN
Li
Qian
Q
Yue
Hua
H
Feng
Jing-kun
JK
Wang
Na
N
D000818:Animals; D017609:Barium Compounds / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D002712:Chlorides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005905:Glyburide / Q000494:pharmacology; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects*; D066298:In Vitro Techniques; D054086:KATP Channels / Q000037:antagonists & inhibitors; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D010946:Plants, Medicinal / Q000737:chemistry; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D024681:Potassium Channels, Calcium-Activated / Q000037:antagonists & inhibitors; D024661:Potassium Channels, Inwardly Rectifying / Q000037:antagonists & inhibitors; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D019789:Tetraethylammonium / Q000494:pharmacology
D017609:Barium Compounds; D002316:Cardiotonic Agents; D002712:Chlorides; D054086:KATP Channels; D026902:Potassium Channel Blockers; D024681:Potassium Channels, Calcium-Activated; D024661:Potassium Channels, Inwardly Rectifying; D013267:Stilbenes; C024986:barium chloride; D019789:Tetraethylammonium; D000077185:Resveratrol; D005905:Glyburide